Skip to content
Screener

Capricor Therapeutics CAPR Q2 2026 earnings

Reported August 14, 2026 · After market close

EPS-$0.70Miss by $0.11
Revenue estimate$2.1M
EPS estimate-$0.59

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$41.7M
EPS estimate-$0.14

Financials

Q2 2026

Income statement

See full
Operating income-$42.9M-54.9%
Net income-$40.7M-57.2%
EPS (diluted)-$0.70-22.8%

Balance sheet

See full
Cash & equivalents$20.9M-9.9%
Total debt$91.0M+8,620%
Total equity$246.2M+135%
Total assets$368.7M+176%

Cash flow

See full
Operating cash flow-$31.5M-56.5%
CapEx$4.1M+1,312%
Free cash flow-$35.5M-74.2%

Valuation & ratios

Valuation

as of 08/27/26
See full
Market cap$544.18M+90.5%
Enterprise value$614.29M+133%

Returns & leverage

See full
Return on equity-73.7%-20.5pp
Debt / equity0.4×+0.4×
Current ratio7.3×+3.0×

FAQ

When did Capricor Therapeutics report Q2 2026 earnings?
Capricor Therapeutics (CAPR) reported Q2 2026 earnings on August 14, 2026 after market close.
What were Capricor Therapeutics's Q2 2026 revenue and EPS?
Capricor Therapeutics reported eps of $-0.70 for Q2 2026.
Did Capricor Therapeutics beat estimates in Q2 2026?
EPS missed the consensus estimate of $-0.59 by $0.11.
How did Capricor Therapeutics's Q2 2026 results compare year-over-year?
Compared to the same quarter a year prior, eps declined 22.8% from $-0.57.
Where can I find Capricor Therapeutics's Q2 2026 SEC filings?
You can read the 8-K earnings release (0001104659-26-095908) and the 10-Q periodic report (0001104659-26-097294) directly on SEC EDGAR. The filing index links above go to sec.gov.